Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Viacom (VIA, VIAB) upgraded to Outperform from Market Perform at Wells Fargo with analyst Marci Ryvicker saying the company's first quarter results prove its turnaround is "real and likely to continue." The strategic plan put in place by CEO Bakish makes sense, Ryvicker tells investors in a research note. The analyst raised his price target range for the shares to $48-$50 from $38-$40. 2. Micron (MU) upgraded to Buy from Underperform at BofA/Merrill. 3. Sanofi (SNY) upgraded to Buy from Neutral at Natixis. 4. Hawaiian Holdings (HA) upgraded to Outperform from Peer Perform at Wolfe Research. 5. Baker Hughes (BHI) upgraded to Positive from Neutral at Susquehanna with analyst Charles Minervino citing the selloff in shares and its upside opportunity associated with a US spending upcycle, synergies from its joint-venture with General Electric (GE), and the growth opportunities that could develop from a partnership with a diversified global oilfield services company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Reports business EPS of EUR 1.78, down 17.6% reported and 7.4% at CER. Reports Q1 IRFS net sales EUR 10.464B, up 2.4%. Paul Hudson, Chief Executive Officer, commented: "We are off to an excellent start in 2024, delivering on our strategic priorities and a transformation of our portfolio of medicines and vaccines to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. Continued strong performance by Dupixent and our new launches drove sales growth of seven percent. In parallel, we are delivering on our promise of increased investments in our late-stage pipeline to fully realize its value for patients and Sanofi. We are awaiting regulatory decisions for Dupixent in COPD, a progressive disease with limited effective treatment options. If approved, Dupixent will be the first biologic treatment in COPD. With the robust progress in our portfolio transformation, we reaffirm our financial guidance for 2024."